MIR105-1

Summary

MIR105-1 (microRNA 105-1, HGNC:31492) is a microRNA gene on chromosome Xq28.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406897 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31492
Approved symbol	MIR105-1
Name	microRNA 105-1
Location	Xq28
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-105-1
Ensembl gene	ENSG00000207957
Ensembl biotype	miRNA
OMIM	300811
Entrez	406897
RNAcentral	URS00004C3DB1 — miRNA, 81 nt, 46 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385222

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385222 — 1 exons

Exon	Start	End
ENSE00001807104	152392219	152392299

Expression profiles

Bgee: expression breadth broad, 15 present calls, max score 72.93.

Top tissues by expression

15 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	72.93	gold quality
intestine	UBERON:0000160	72.31	gold quality
heart left ventricle	UBERON:0002084	70.55	gold quality
gastrocnemius	UBERON:0001388	69.12	gold quality
muscle layer of sigmoid colon	UBERON:0035805	68.10	gold quality
subcutaneous adipose tissue	UBERON:0002190	65.94	gold quality
tibial nerve	UBERON:0001323	64.02	gold quality
amygdala	UBERON:0001876	63.08	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	61.96	gold quality
spleen	UBERON:0002106	60.71	gold quality
thoracic mammary gland	UBERON:0005200	59.77	gold quality
Brodmann (1909) area 9	UBERON:0013540	59.17	gold quality
lung	UBERON:0002048	58.96	gold quality
left lobe of thyroid gland	UBERON:0001120	58.84	gold quality
left testis	UBERON:0004533	29.61	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.16

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 19)

• Data indicate CDK6 as a putative target of miR-105 which is likely a main contributor to the inhibition of tumour cell growth observed in our assays. (PMID:23950948)
• Data indicate that adult CD34(+) cells express endogenous miR-105 during megakaryocyte differentiation. (PMID:24446170)
• Low MIR105 is associated with hepatocellular carcinoma. (PMID:25280563)
• miR-105/Runx2 axis mediates FGF2-induced ADAMTS expression in osteoarthritis cartilage. (PMID:26816250)
• Results provide the first evidence that NCOA1 is a direct target of miR-105-1 suggesting that NCOA1 and miR-105-1 may have potential prognostic value and may be useful as tumor biomarkers for the diagnosis of HCC patients. (PMID:28060733)
• Our data demonstrate that miR-105 inhibits gastric cancer cell proliferation and progression, which might provide a therapeutical target for cancer therapy. (PMID:28829505)
• miR-105 promotes MYC-mediated metabolic reprogramming of breast cancer stromal cells, contributing to sustained tumour growth by conditioning the shared metabolic environment. (PMID:29662176)
• Up-regulation of miRNA-105 inhibits the progression of gastric carcinoma by directly targeting SOX9. (PMID:31115004)
• MiR-105 inhibits gastric cancer cells metastasis, epithelial-mesenchymal transition by targeting SOX9. (PMID:31364116)
• Higher level of miR-105-1 predicts poorer prognosis in esophageal cancer patients, and miR-105 can promote esophageal cancer cell proliferation, migration, and invasion. (PMID:31796663)
• Knockdown of long non-coding RNA VIM-AS1 inhibits glioma cell proliferation and migration, and increases the cell apoptosis via modulation of WEE1 targeted by miR-105-5p. (PMID:32633376)
• Cancer-secreted miRNAs regulate amino-acid-induced mTORC1 signaling and fibroblast protein synthesis. (PMID:33345445)
• Hsa-miR-105-1 Regulates Cisplatin-Resistance in Ovarian Carcinoma Cells by Targeting ANXA9. (PMID:33680718)
• MiR-105-3p acts as an oncogene to promote the proliferation and metastasis of breast cancer cells by targeting GOLIM4. (PMID:33722196)
• MiR-105 enhances osteogenic differentiation of hADSCs via the targeted regulation of SOX9. (PMID:33838353)
• Role of hsamiR105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer. (PMID:33846814)
• miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer. (PMID:34098061)
• Exosomal miR-105-5p derived from bladder cancer stem cells targets for GPR12 to promote the malignancy of bladder cancer. (PMID:37789353)
• Circular RNA circMRPS35 represses malignant progression in osteosarcoma cells via targeting miR-105-5p/FOXO1. (PMID:39103205)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir105	ENSMUSG00000077847

Paralogs (1): MIR105-2 (ENSG00000207818)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.